Toll Free #:1800-4259-3333

Your Liver.
Your Life.
Our Experts.

Good liver health begins with you


Dr Anil Vaidya is a multi-organ transplant surgeon with a varied clinical, translational and academic portfolio. After completion of his surgical/urological residency he went on to do an American Society of Transplant Surgeons (ASTS) accredited fellowship in multi-organ transplantationat the University of Miami.

He has been a Consultant Transplant Surgeon at the Oxford University Hospitals for 11 years where his main focus was on developing a robust pancreatic, intestinal and multi-visceral transplant program. With his leadership, the Oxford Transplant Centre is now by far the largest Pancreas Transplant Centre in Europe and fast becoming the Centre known for the most amount of Pancreas alone transplants worldwide.

He is responsible for restarting the intestinal transplant program in the UK and bring it onto the map in the intestinal transplant community by organizing the International Conference for intestinal Transplant, biennial meeting at Oxford in 2013.

Dr Vaidya's profile includes a few firsts:

  1. A world-first ground breaking multi-organ transplant, for Pseudo-Myxoma Peritonei, a disease that had no treatment until now. This has now become standard practice for patients with Pseudo-myxoma Peritonei, who fail conventional methods of therapy.
  2. He is credited for having done the first composite tissue allograft (CTA) transplant in the UK in the form of vascularised abdominal wall transplantation to complement intestinal transplantation.
  3. He currently holds the largest series of cases of abdominal wall transplants.
  4. He is the first surgeon in the world to do a sentinel skin flap with a multi-visceral graft to help in monitoring the intestinal graft.
  5. He was the first surgeon in the world to introduce the concept of 'nephron sparing' auto-transplantation for solitary kidneys with tumours.
  6. He currently has the world's largest successful series of renal auto-transplants for solitary kidneys with cancer.
  7. He remains one of the few surgeons in the world who has done over 1000 pancreas transplants.
  8. In October 2013, Dr. Vaidya became the first surgeon to successfully use Stem Cells to treat a patient with bowel dysfunction after intestinal transplantation.
  9. He is the first Surgeon in the world to have successfully re-transplanted a composite tissue allograft.

Apart from clinical kidney, pancreas and intestinal transplantation, his areas of translational research interest include developing novel strategies for improved graft surveillance and survival. At Oxford, they averaged 80-90 pancreas transplants a year with a big focus on deceased donor and extended criteria pancreas transplantation. The program does about 150-180 kidneys a year and has an active ABO and highly sensitized kidney transplant service including paired exchanges.

In addition to the pancreas and kidney-transplant service, he has been the pioneer for the intestinal transplant service. Here they averaged about 35 transplants in the last 5 years, with an 80% 3-year graft and patient survival. Six of their 25 patients have now reached the 5-year mark with their first grafts.


Dr Vaidya has authored more than a 100 articles in peer-reviewed journals and continues to be very interested in active writing and publishing scientific data. His rating by Research Gate puts him among the top 5% of the surgeons in the world.

Teaching Experience:

He has a passion for education and has been a post-graduate teacher, as well as under-graduate teacher for over 10 years at Oxford. This has involved playing an active role in teaching the allocated medical students according to a pre-set syllabus. He has been a post-graduate teacher who has been involved with didactic teaching sessions for the residents in the hospital as well as in the region. Furthermore, he is a post graduate supervisor with access to resident's log books and is involved in the certification process for these residents during their tenure in the hospital. He has a keen interest in teaching operative skills and often embarks on that track in the operating room.

Research Interests

A. Intestinal Transplantation:

  1. Interest in developing patient-led remote methods of immune monitoring for visceral transplants. This includes the use of vascularized sentinel skin flaps from the same donor.
  2. Abdominal wall transplantation to complement intestinal transplantation.
  3. Developing the use of Mesenchymal Stromal Cells (MSC) in intestinal transplantation.
  4. Developed a scoring system to design a pathway for referrals for intestinal transplantation in Crohn's disease.
  5. Major interest in the role of Intestinal transplantation for slow growing tumours in the abdominal cavity, especially neuro-endocrine tumours (NETs) and pseudomyxoma-peritonei (PMP).

B. Pancreas Transplantation:

  1. Optimal use of pancreas grafts from extended criteria donors.
  2. Patient led remote immune monitoring of pancreas graft.
  3. Radiologic methods of determining functional islet cell mass in transplanted grafts.
  4. Determining the volume of apoptotic signals from a transplanted pancreas for longitudinal monitoring of the graft.
  5. Development of alternate sites for pancreatic islet cell infusion.
  6. Pharmacological and immunological rescue therapy for failing pancreas grafts.

C. Auto-transplantation:

  1. Key role in developing a renal auto-transplant service in the UK for solitary kidneys with tumours not resectable by conventional means.
  2. Interest in auto-transplantation for slow growing tumours in the abdominal cavity.
  3. Expanding the role of auto-transplantation for major visceral trauma.

D. Translational medicine

  1. Normothermic preservation of ECD pancreas and kidney before transplantation.
  2. Patient-led immunological monitoring of visceral graft with sentinel skin flap from the same donor.
  3. Evaluating and defining skin characteristics in patients with a vascularised sentinel skin or a vascularised composite abdominal wall transplant.
  4. Radiological imaging of beta cells after whole organ transplantation.
  5. Rescue therapy of a failing whole organ pancreas graft.
  6. Lymphatic activation markers after intestinal transplantation.
  7. Developing a tissue engineered pancreas unit using vascularised donor strattice as alternate sites of islets infusion.